LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 90 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q4 2020. The put-call ratio across all filers is 0.05 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $17,700 | -16.3% | 15,000 | 0.0% | 0.01% | -16.7% |
Q2 2023 | $21,150 | -6.0% | 15,000 | 0.0% | 0.01% | -14.3% |
Q1 2023 | $22,500 | +28.2% | 15,000 | 0.0% | 0.01% | +16.7% |
Q4 2022 | $17,550 | +3.2% | 15,000 | 0.0% | 0.01% | 0.0% |
Q3 2022 | $17,000 | -29.2% | 15,000 | 0.0% | 0.01% | -25.0% |
Q2 2022 | $24,000 | +4.3% | 15,000 | 0.0% | 0.01% | +33.3% |
Q1 2022 | $23,000 | -37.8% | 15,000 | 0.0% | 0.01% | -33.3% |
Q4 2021 | $37,000 | -2.6% | 15,000 | 0.0% | 0.01% | -10.0% |
Q3 2021 | $38,000 | -11.6% | 15,000 | 0.0% | 0.01% | -16.7% |
Q2 2021 | $43,000 | +7.5% | 15,000 | 0.0% | 0.01% | +9.1% |
Q1 2021 | $40,000 | +53.8% | 15,000 | 0.0% | 0.01% | +37.5% |
Q4 2020 | $26,000 | +85.7% | 15,000 | 0.0% | 0.01% | +60.0% |
Q3 2020 | $14,000 | +7.7% | 15,000 | 0.0% | 0.01% | 0.0% |
Q2 2020 | $13,000 | +8.3% | 15,000 | 0.0% | 0.01% | -16.7% |
Q1 2020 | $12,000 | -7.7% | 15,000 | 0.0% | 0.01% | +50.0% |
Q4 2019 | $13,000 | – | 15,000 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Defender Capital, LLC. | 4,735,990 | $8,335,000 | 3.63% |
BROADWOOD CAPITAL INC | 34,005,379 | $59,849,000 | 3.55% |
Prescott General Partners LLC | 1,851,851 | $3,259,000 | 0.14% |
Strategic Wealth Investment Group, LLC | 66,917 | $118,000 | 0.07% |
Laidlaw Wealth Management LLC | 170,658 | $300,000 | 0.06% |
Humankind Investments LLC | 26,737 | $47,000 | 0.05% |
DAFNA Capital Management LLC | 80,000 | $141,000 | 0.04% |
Beirne Wealth Consulting Services, LLC | 45,000 | $79,000 | 0.04% |
BRIDGEWAY CAPITAL MANAGEMENT, LLC | 680,839 | $1,198,000 | 0.02% |
Allegheny Financial Group LTD | 20,000 | $35,000 | 0.02% |